The World Stroke Organization’s Declaration for worldwide primary stroke and dementia prevention

Cover Page

Cite item

Full Text


Сurrent strategies of primary stroke and cardiovascular disease prevention are aimed at addressing the main risk factors primarily in patients with higher cardiovascular disease risk. Since the number of people with incident stroke and ischaemic heart disease cases is rapidly growing across all countries of the world, this preventive strategy appears to be not sufficiently effective. World Stroke Organization recently (2020) endorsed a different concept of stroke and dementia prevention based on a population-wide approach to dealing with risk factors, which involves all individuals regardless of their cardiovascular disease risk level. This article describes four main primary prevention strategies suggested by the World Stroke Organization to effectively reduce stroke and dementia incidence by 50% and 30% respectively. These strategies include (1) population-wide prevention; (2) polypill therapy; (3) free e-Health application “Stroke Riskometer”; and active engagement of community health workers.

About the authors

Michael Brainin

Danube University

Austria, Krems

Valery l Feigin

Auckland University of Technology

Author for correspondence.
New Zealand, Auckland

Bo Norrving

Lund University

Sweden, Lund

Sheila C.O. Martins

Hospital de Clínicas de Porto Alegre

Brazil, Porto Alegre

Graeme J. Hankey

The University of Western Australia

Australia, Perth

Vladimir Hachinski

Western University

Canada, Ontario


  1. Hankey Graeme J. Population impact of potentially modifiable risk factors for stroke. Stroke 2020; 51: 719–728. doi: 10.1161/STROKEAHA.119.024154. PMID: 32078497.
  2. Hachinski V., Einhäupl K., Ganten D. et al. Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement 2019; 15: 961–984. doi: 10.1016/j.jalz.2019.06.001. PMID: 31327392.
  3. Feigin V.L., Brainin M., Norrving B. et al. What is the best mix of population-wide and high-risk targeted strategies of primary stroke and cardiovascular disease prevention? J Am Heart Assoc 2020; 9: e014494. DOI: 10.1161/ JAHA.119.014494. PMID: 31983323.
  4. Krogsboll L.T., Jorgensen K.J., Gotzsche P.C. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2019; 1: CD009009. doi: 10.1002/14651858.CD009009.pub3. PMID: 30699470.
  5. Chiuve S.E., Rexrode K.M., Spiegelman D. et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118: 947–954. doi: 10.1161/CIRCULA- TIONAHA.108.781062. PMID: 18697819.
  6. Brainin M., Feigin V., Martins S. et al. Cut stroke in half: Polyp- ill for primary prevention in stroke. Int J Stroke 2018; 13: 633–647. doi: 10.1177/1747493018761190. PMID: 29461155.
  7. Gulliford M., Alageel S. Digital health intervention at older ages. Lancet Digital Health 2019; 1: e382–e383. DOI: 7500(19)30194-3.
  8. Krishnamurthi R., Hale L., Barker-Colllo S. et al. Mobile technology for primary stroke prevention: a proof-of-concept pilot randomised controlled trial. Stroke 2018; 50: 196–198. doi: 10.1161/STROKEAHA.118.023058. PMID: 30580699.
  9. Feigin V.L., Norrving B., Mensah G.A. Primary prevention of cardiovascular disease through population-wide motivational strategies: insights from using smartphones in stroke prevention. BMJ Global Health 2017; 2: e000306): doi: 10.1136/bmjgh-2017-000306. PMID: 28589034.
  10. Ngandu T., Lehtisalo J., Solomon A. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 2015; 385: 2255–2263. doi: 10.1016/S0140- 6736(15)60461-5. PMID: 25771249.
  11. Ding J., Davis-Plourde K.L., Sedaghat S. et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol 2020; 19: 61–70. doi: 10.1016/S1474-4422(19)30393-X. PMID: 31706889.
  12. Elley C.R., Gupta A.K., Webster R. et al. The efficacy and tolerability of ‘polypills’: meta-analysis of randomised controlled trials. PLoS One 2012; 7(12): e52145. doi: 10.1371/journal.pone.0052145. PMID: 23284906.
  13. Roshandel G., Khoshnia M., Poustchi H. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019; 394: 672–683. DOI: 10.1016/ S0140-6736(19)31791-X. PMID: 31448738.
  14. Muñoz D., Uzoije P., Reynolds C. et al. Polypill for cardiovascular disease prevention in an underserved population. New Engl J Med 2019; 381: 1114–1123. doi: 10.1056/NEJMoa1815359. PMID: 31532959.
  15. Yusuf S., Lonn E., Pais P. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. New Engl J Med 2016; 374: 2032–2043. doi: 10.1056/NEJMoa1600177. PMID: 27039945.
  16. Jeet G., Thakur J.S., Prinja S., Singh M. Community health workers for non-communicable diseases prevention and control in developing countries: Evidence and implications. PLoS One 2017; 12: e0180640. doi: 10.1371/journal. pone.0180640. PMID: 28704405.
  17. Brainin M., Feigin V., Bath P.M. et al. Multi-level community interventions for primary stroke prevention: A conceptual approach by the World Stroke Organization. Int J Stroke 2019; 14: 818–825. doi: 10.1177/1747493019873706. PMID: 31500553.

Supplementary files

Supplementary Files

Copyright (c) 2020 Brainin M., Feigin V.l., Norrving B., Martins S.C., Hankey G.J., Hachinski V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies